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Abstract27
RNA transcripts of the B7 family molecule (CD80) are diminished in blood leukocytes from 28
animals clinically affected with Visna/Maedi virus (VMV) infection. This work investigates 29
whether the use of B7 genes enhances immune responses and protection in immunization-30
challenge approaches. Sheep were primed by particle-mediated epidermal bombardment with 31
VMV gag and env gene recombinant plasmids together with plasmids encoding both CD80 and 32
CD86 or CD80 alone, boosted with gag and env gene recombinant modified Vaccinia Ankara 33
virus and challenged intratracheally with VMV. Immunization in the presence of one or both of 34
the B7 genes resulted in CD4+ T-cell activation and antibody production (before and after 35
challenge, respectively), but only immunization with CD80 and CD86 genes together, and not 36
CD80 alone, resulted in a reduced number of infected animals and increased early transient CTL 37
responses. Post-mortem analysis showed an immune activation of lymphoid tissue in challenge-38
target organs in those animals that had received B7 genes compared to unvaccinated animals. 39
Thus, the inclusion of B7 genes helped to enhance early cellular responses and protection 40
against VMV infection.41
42
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1. Introduction48
49
Small ruminant lentiviruses (SRLV) include Visna/Maedi Virus (VMV) and caprine 50
arthritis-encephalitis virus (CAEV). SRLV infect the monocyte/macrophage lineage in sheep 51
and goats and cause chronic inflammatory lesions in the lung, carpal joints, mammary glands, 52
and brain in these ruminant species [1]. SRLV are widely spread and strategies based on early 53
diagnosis, management and culling of seropositive animals have been applied in order to 54
eradicate infection. In natural SRLV infections of small ruminants, the response of the immune 55
system to virus in tissues may lead to pathology [2-6], which may increase in heavily infected 56
animals [2, 7, 8] till the animal’s death. Although vaccination may prevent infection, minimize 57
clinical symptoms or delay the onset of disease resulting in an improvement of animal welfare 58
and avoidance of production losses (reviewed in [9]), efficient immunoprophylactic tools have 59
not been developed against SRLV and immunization has not conferred sterilizing immunity so 60
far. 61
DNA vaccination is an alternative approach to conventional vaccines, triggering both 62
antibody and cell-mediated immune responses [10]. In goats, SRLV immunization with env63
plasmids has led to decreased viral replication and load and diminished disease [11] whilst gag64
gene or peptide immunization has resulted in enhancement of proviral load or disease [12, 13]. 65
In sheep, immunization may lead to protection against early lesion development or against viral 66
infection (decreased load) [14-16]. Vaccination with inactivated virus leads to disease [12, 17, 67
18], but using an attenuated VMV clone results in a diminished number of viral isolations after 68
challenge [19]. Mucosal immunization using plasmids containing VMV env confers a protective 69
effect seen by decreased proviral load [14, 16], whilst the use of the gag gene enhances 70
protection against early lesion development [16]. When the same plasmids are delivered 71
intradermally and this is followed by modified vaccinia Ankara virus (MVA) boosting, only the 72
gag gene (or gag in combination with env) gives rise to partial protection against infection [15], 73
but when the vaccination protocol is changed [20], pre-existing immune responses to GAG74
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proteins do not prevent infection. Thus, immunization routes and viral genes used clearly affect 75
the results of vaccination. 76
One of the limiting factors in DNA vaccination is antigen presentation after host-cell 77
transfection with exogenous DNA [21]. Full activation of T cells requires both an antigen-78
specific stimulus provided by MHC-peptide complex and a costimulatory signal [22, 23]. The 79
engagement of CD28 on the surface of T cells by the costimulatory B7-1 (CD80) [24, 25] or 80
B7-2 (CD86) [26, 27] molecules expressed by antigen presenting cells (APCs) provides a potent 81
costimulatory signal, leading to T cell proliferation, differentiation, and cytokine production. 82
However, CD80 and CD86 have higher affinity for the T cell inhibitory receptor CTLA-4 than 83
for CD28 [28, 29]. This receptor is up-regulated after T cell activation and it is suggested that 84
these interactions are important in helping to curb T cell responses. CD86 exhibits faster 85
dissociation kinetics than CD80 in interactions with both CD28 and CTLA-4 [29]. Also CD86 is 86
constitutively expressed on B cells, monocytes and dendritic cells whilst CD80 is inducible [23, 87
26]. Therefore, CD80 and CD86 appear to have functional differences in T cell activation. 88
Ovine CD80 [30] and CD86 [31] genes have been identified recently. The mRNA levels 89
of these molecules in peripheral blood mononuclear cells (PBMC) have been studied at different 90
stages of SRLV infection [32], being increased in VMV-infected asymptomatic sheep and 91
associated with positive VMV-specific T-cell proliferative responses. In contrast, low levels of 92
these molecules (especially of CD80) are found in clinically affected sheep, being associated 93
with impairment of antigen-specific cellular recall responses. 94
This study investigates the immune responses and degree of protection, against viral 95
infection (load) and/or immunity-related lesion development, obtained by particle-mediated 96
epidermal delivery (PMED) immunization of sheep against VMV, priming with plasmids 97
encoding VMV (gag and env) genes together with plasmids encoding B7 genes (CD80 and 98
CD86) or CD80 gene alone, and using a recombinant MVA for booster immunization. 99
100
2. Materials and methods101
102
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2.1. Animals103
104
Thirty castrated one year old males from a VMV-free certified flock belonging to the 105
Lleyn sheep breed from the United Kingdom were used to avoid possible breed effects in 106
comparisons with previous studies involving similar immunization schemes. Absence of VMV 107
infection was confirmed by a commercial ELISA (Elitest MVV/CAEV, Hyphen Biomed) and 108
PCR (as described below). The animal experiments were performed following national 109
regulations and institutional guidelines.110
111
2.2. Plasmids and recombinant modified vaccinia virus Ankara used for immunization112
113
Plasmids used for immunizations were derivates of pN3, generated from pEGFP-N3 114
(Clontech Laboratories, Inc) by removing the EGFP gene, and which contains the eukaryotic 115
HCMV immediate early promoter to drive expression of the gene of interest. pN3 was used as 116
the control empty plasmid in immunizations and also to make pN3-gag and pN3-env, which 117
encode the VMV gag p55 and env gp150 genes (EV1 strain, [33, 34]) previously used in other 118
vaccination studies [15, 16]. Large-scale preparations of endotoxin-free plasmid DNA were 119
made using a commercial maxi-prep kit (Qiagen Ltd.) according to the manufacturer’s 120
instructions. Expression of p55 GAG and gp150 ENV was determined by RT-PCR and Western 121
Blotting (WB) [16, 34].122
Ovine CD80 (AY390555) and CD86 (AY491977) cDNA, cloned into pGEM-T easy 123
plasmids [30, 31], were sub-cloned into the eukaryotic expression plasmid pN3 to produce pN3-124
CD80 and pN3-CD86, respectively. Expression of pN3-CD80 and pN3-CD86 was assessed by125
specific mRNA transcription in transfected ovine skin fibroblasts using RT-PCR using the 126
following primers: forward SG80sFW 5´- CAT CAC CCC AAA GAG CGT G -3´ and reverse 127
B7-1RV 5´- TGG AAA ACC TCC AGA GG -3´ to amplify a 415 nucleotide (nt) region of the 128
ovine CD80 cDNA; and forward CD86-TM-FW 5´- GAC AAT CTT CTG TGT CCT GCA 129
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ACT TGA GCC -3´ and reverse CD86-2RV 5´- TCC AGG TTT TTG GAG TTC TAC CC –3´ 130
to amplify a 110 nt region of the ovine CD86 cDNA.131
Plasmid transfection was performed with Lipofectamine 2000 (Invitrogen) in monolayers 132
of ovine skin fibroblasts, as specified by the manufacturer. Transfected cells were incubated for 133
48 h and total RNA extracted and analyzed by RT-PCR for the presence of CD80 or CD86 134
RNA. Using the appropriate controls (eg no RT, empty vector transfected cells) both the CD80 135
and CD86 expression plasmids were shown to express the appropriate RNA (data not shown). 136
MVA virus expressing either the gag p55 (MVA-gag) or the env gp150 (MVA-env) genes of 137
VMV EV1 were used for immunization as described previously [16, 34]. For the control group, 138
immunization with recombinant MVA expressing ß-galactosidase (MVA-pSC11) was used. 139
Viral protein expression was determined by WB using anti-GAG and anti-ENV specific rabbit 140
sera [34]. 141
142
2.3. Preparation of DNA-coated gold particles for gene gun immunization143
144
Gene gun parameters used for immunization were as previously described [15, 35]. DNA 145
plasmids were precipitated onto gold particles (BioRad Laboratories Ltd.) resulting in a DNA 146
loading ratio of 4 µg/mg of gold. The mixture was allowed to precipitate, washed in dehydrated 147
99.9% ethanol (VWR International Ltd.) and then re-suspended in ethanol containing 148
polyvinylpyrrolidone. Each cartridge contained approximately 1 µg of plasmid DNA. Delivery 149
was performed intradermally using the Helios Gene gun system (BioRad Laboratories Ltd.). 150
The gene gun discharge pressure used to propel the DNA-coated gold particles into the dermal-151
epidermal junction was 435 psi.152
153
2.4. Expression and purification of recombinant GAG proteins and mock protein preparations154
155
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Plasmids (pRSET) containing VMV strain EV1 gag p14, p17 and p25 [36] were used 156
once sequences were verified. Recombinant p14, p17, p25 and mock preparations were 157
produced as described previously [16]. 158
159
2.5. Immunization and challenge160
161
Table 1 shows the immunization groups and number of animals used. All groups received 162
a total of 30 µg of DNA per animal by gene gun at weeks 0 and 4 (10 μg of each plasmid except 163
the gag-env-CD80-CD86 group that received 10 μg of each VMV plasmid and 5 μg each of the 164
CD80 and CD86 plasmids). The same sheep were boosted subcutaneously at week 10 with 165
recombinant MVA-gag and MVA-env (108 pfu each). The control group received MVA-pSC11 166
(2 x 108 pfu).  167
VMV strain EV1 [33] grown and titrated as described previously [37] was used to 168
challenge sheep with 1 × 103 TCID50 in 1 mL of PBS 12 weeks after priming via the intra-169
tracheal route, as described elsewhere [38]. 170
171
2.6. Sampling172
173
Blood samples were collected before priming (hereafter called week 0), after DNA 174
priming (week 7), after recombinant MVA boosting but before challenge (week 12), and after 175
VMV challenge at different time-points (weeks 16, 20 and 24, that is weeks 4, 8 and 12 post-176
challenge). Sheep were euthanised and necropsied 25 weeks after the start of the experiment (13 177
weeks post-challenge). Lung lobes and mediastinal lymph node (MLN) samples were taken as 178
previously described [15, 16].179
180
2.7 Measurement of anti-VMV antibodies181
182
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The presence of VMV-specific antibodies was assessed in serum after immunization and 183
challenge using a commercial VMV antibody ELISA test (Elitest®, from Hyphen Biomed, 184
Neuville-sur Oise, France) that employs as plate coating VMV antigens a synthetic peptide of 185
the ENV transmembrane protein (TM) and recombinant GAG p25 protein [39]. Samples were 186
analyzed in duplicate. The ELISA score (optical density, O.D. ratio) was calculated as the ratio 187
between the mean absorbance (A450) of a sample and the mean absorbance of the kit controls 188
(cut-off), according to the manufacturer’s instructions. ELISA scores ≥ 1 were considered 189
positive. 190
An ELISA method using whole virus for coating (140 ngr per well) was applied as 191
previously described [16]. The positivity threshold was established for each plate as the mean 192
O.D. value of known negative serum samples plus two times the standard deviation (mean + 193
2S.D.). Dilution series of sera were started at 1 in 100. The reciprocal of the last positive serum 194
dilution was taken as the antibody titre and results were expressed as a box plot which includes 195
the median value and the interquartile range.196
Neutralizing antibody (NtAb) determinations were performed in six replicates (100 197
TCID50 virus per well) as previously described [19] except that the incubation of the virus with 198
serum at the different dilutions was done for 36 h and the cells used for the assay were 199
monolayers of GSM-T ß-gal cultures (kindly supplied by Dr. Valas, AFSSA, Niort, France). 200
These cells were incubated with the mixture for 10 days, fixed and stained with X-gal. GSM-T 201
-gal cells are goat synovial membrane cells transfected and permanently expressing a -202
galactosidase construct that contains a Rev Responsive Element (RRE) so that -galactosidase 203
protein is only expressed if Rev protein of the virus is present [40]. Thus, the presence of the 204
virus in the supernatant was determined by blue staining due to the presence of the REV protein. 205
NtAb titres of sera were calculated as the reciprocal of the serum dilution that caused loss of 206
infectivity in 50% of inoculated cultures. Control cultures were inoculated with virus in the 207
absence of antiserum. 208
To detect antibody by WB, virus antigen was diluted with 125 µl of lysis buffer (0.05 M 209
Tris pH 7.2, 0.15 M NaCl, 0.1% SDS, 1% Triton X-100, 1% deoxycholate, 1 mM 210
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phenylmethyl-sulfonyl fluoride) and 125 µl of loading buffer (0.5 M Tris HCl pH 6.8, SDS 2%, 211
glycerol 10%, dithiothreitol 0.1 M, bromophenol blue), applied to a 4% stacking gel and a 12% 212
gradient separation gel and blotted onto a nitrocellulose transfer membrane after electrophoresis. 213
Transfer was carried out at 4°C for 75 min in 0.25 M Tris, 1.92 M glycine, 20% methanol and 214
0.01% SDS, at 100 V and 250 mA. After transfer, the membrane was blocked for at least 1 h at 215
37°C with PBS containing 0.2% Tween 20 (PBS-T) and 3% bovine serum albumin (BSA).216
After blocking, the membrane was cut into strips and incubated with serum samples diluted 217
1:100 for 1 h at 37°C with shaking. Rabbit anti-sheep IgG conjugated to peroxidase was used at 218
a dilution of 1:2,000 in PBS-T with 1% BSA for 1 h at 37°C and reactions were developed 219
using Chemiluminescence (Amersham ECL Western blotting detection reagents, GE 220
Healthcare). 221
222
2.8. Measurement of anti-VMV T cell reactivity 223
224
Heparinized blood was collected (10 U/mL final) and PBMC isolated on a Ficoll-225
Hypaque gradient ( = 1.077; Lymphoprep, Axis-Shield), then suspended in RPMI-1640 226
medium with 25 mM HEPES (Sigma-Aldrich Company Ltd), supplemented with 2 mM L-227
glutamine, 50 µM beta-mercaptoethanol, 100 U penicillin and 100 µg streptomycin/mL, 2.5 µg 228
amphotericin B/mL and 10% foetal calf serum (FCS) (10%RPMI).229
A cytotoxic assay was performed for the detection of precursor cytotoxic T lymphocytes 230
(CTL). Animals were deemed to show the presence of CTL if the percentage specific 51Cr 231
release from VMV infected minus mock infected autologous cells was >10% above that from 232
heterologous infected minus mock infected cells [16], in which the killing of mock infected and 233
heterologous cells was less than 10%. The frequency of CTL positive animals was used for 234
analysis of results. VMV GAG-specific T cell proliferative and CTL responses were compared 235
within and between groups throughout the experimental period using PBMC.236
T cell proliferation assays were performed in quadruplicate as described elsewhere [16]. 237
Briefly, 105 PBMC in 10% RPMI were mixed with different dilutions of recombinant GAG238
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
proteins (from 50 μg/mL to 6.25 μg/mL for p25 and p14; and from 25 μg/mL to 3.12 μg/mL for 239
p17). Positive Concanavalin A (ConA at 5 g/mL) and negative (mock antigen) controls were 240
included. Cells were labelled with [3H] thymidine (0.037 MBq/well, GE Healthcare) and 241
cellular proliferation assessed by measuring the incorporation of [3H] into the cells (cpm). The 242
stimulation index (S.I.) was calculated for each antigen using the formula S.I. = cpm with 243
antigen/cpm with mock antigen. Results were analysed using the median stimulation indices of 244
all dilutions for each protein. An individual animal was considered to show positive T cell 245
reactivity if the stimulation index was greater than 3. 246
247
2.9. Measurement of proviral load 248
249
2.9.1. Proviral load in blood250
EDTA blood (8 mL) was collected at each time point and PBMC isolated on a Ficoll-251
Hypaque gradient ( = 1.077; Lymphoprep, Axis-Shield). Following erythrocyte lysis, genomic 252
DNA was extracted with a QIAamp DNA Blood Mini Kit (Qiagen Ltd.) according to the 253
manufacturer’s instructions. DNA was quantified by spectrophotometry (Bio-Rad SmartSpec 254
Plus Spectrophotometer, Bio-Rad) and a final concentration of 100 ng/l was used. Five 255
microliters of freshly prepared DNA were used in a 25 μl real-time PCR assay specific for 256
VMV gag p25. Gag amplicon length was 106 nt. Primers and probe sequences were as follows: 257
sense primer S2:  5’ – TCAACAGGCATCACAGGCTAATA – 3’ (nt. 1249-1271); antisense 258
primer AS2:  5’ – GTTACCTGGCCTATGCGACAT – 3’ (nt. 1334-1353); antisense probe:  5’ 259
– ACCGCTCTCAAGGCTGTTATGACCCA – 3’ (nt. 1301-1325). Nucleotide positions refer to 260
the published EV1 strain sequence [33]. A dual-labelled probe (Operon) was used with 6-FAM 261
as the 5' fluorophore and a 3' Black Hole Quencher (BHQ1a-Q). DNA samples were tested three 262
times in triplicate (9 replicates in all). Ten fold serial dilutions of a plasmid (pDRIVE, Qiagen 263
Ltd.) carrying a 567 bp EV1 gag fragment (nt. 963 to 1529) were used to generate the standard 264
curve. Plasmid copy numbers ranged from 10 to 106 per reaction. Positive and negative controls 265
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were included in each assay. Reactions were carried out in an ABI 7900 system (Applied 266
Biosystems), with the following thermal profile: 10 min at 95°C and then 45 cycles of 95°C 15 s 267
and 60°C 1 min. 268
Mean copy number per reaction was converted to mean copy number per microgram of 269
template DNA for each animal. Animals which showed positive proviral load in at least one 270
time point of the three time points tested (weeks 16, 20 and 24) in the post-challenge period, 271
were considered infected. 272
273
2.9.2. Proviral load in tissues274
One hundred milligrams of tissue from MLN and lung sections as for the pathological 275
evaluation (four lobes of the lung or the MLN, see below) were taken at necropsy and stored in 276
RNA Later (Qiagen Ltd.) at -80°C. Tissue samples were minced with a scalpel and 277
homogenized with a pestle in 680 µl of lysis buffer (NaCl 5M, Tris-HCl 1M pH 8.5, EDTA 278
0.5M, SDS 10%). Following incubation with proteinase K at 56°C, DNA was extracted and the 279
proviral copy number measured, as described above, from each lung piece and lymph node. 280
Mean copy number per reaction was converted to mean copy number per microgram of 281
template DNA for each animal. Animals were considered positive if the provirus was detected 282
in at least one of the tissue sections analysed. 283
284
2.10. Pathology studies285
286
Lungs were removed aseptically and studied first macroscopically for pathological 287
changes (colour, consistence, size and weight). Samples from 4 different lung lobes (the right 288
accessory cranial lobe, the right apical medial lobe, the right caudal lobe and the left cardiac 289
cranial lobe) and MLN were taken for histological studies. Tissues were fixed in 10% 290
phosphate-buffered formalin (Sigma), embedded in paraffin and sectioned according to standard 291
procedures. Sections were stained with Hematoxylin-Eosin and scored blind for pathology by 292
two independent pathologists. 293
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Histological changes in lung and MLN were scored: in the lung, lymphoid follicle 294
hyperplasia and interstitial pneumonia as well as bronchial associated lymphoid tissue 295
hyperplasia and perivascular infiltrates were scored on a scale of 0-3; and in the MLN, 296
lymphoid follicle reactivity and cortical hyperplasia were scored on a scale of 0-1. The mean of 297
all scores was used for each animal. 298
299
2.11. Statistical analysis300
301
Fisher’s exact test was used for comparisons on frequency of individuals positive at each 302
time point. Between and within group comparisons of medians at each time point were done 303
with Mann-Whitney and Wilcoxon rank tests, respectively. Differences were considered 304
significant if p 0.05. 305
306
3. Results307
308
3.1. Cellular immune responses  309
310
3.1.1 Cytotoxic T lymphocyte response311
Although CTL reactivity was generally low, differences in the proportion of CTL-positive 312
animals were found among the study groups (Fig. 1). In the control group, no evidence of CTL 313
response was detected in the pre-challenge period (Fig. 1A) and the percentage of positive 314
animals in the post-challenge period was similar to that found in the groups receiving B7. In the315
gag-env immunized group, CTL activity was found after the MVA boost (week 12), resulting in 316
over 50 percent positive animals; but the highest activity was reached at week 20, with more 317
than 80 percent positive animals (Fig. 1B). In this group, statistical differences were found 318
significant between the pre-challenge (weeks 0 and 7) and the post-challenge (week 20) periods. 319
In the gag-env-CD80 group, CTL positive animals appeared at week 7 as a result of plasmid 320
immunization in 25 percent of the animals (Fig. 1C). This low proportion was maintained until 321
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week 16. By the end of the experimental period CTL activity decreased (12.5% positive animals) 322
but did not disappear. In the gag-env-CD80-CD86 group, the highest proportion of CTL 323
positive animals was reached early after immunization (week 7, 63%), significantly increased 324
compared to week 0. The number of CTL positive animals decreased thereafter, especially post-325
challenge, until disappearing by the end of the experimental period (Fig. 1D). 326
A comparative analysis between groups revealed a very significantly increased proportion 327
of CTL positive animals at week 7 in the gag-env-CD80-CD86 group (63 percent) compared to 328
control and gag-env groups (both 0 percent). In contrast, both B7 immunized groups had 329
significantly decreased numbers of CTL positive animals than the gag-env group (12.5 percent 330
in each B7 group vs. 85.7 percent in the gag-env group) at week 20. 331
Overall these results indicate that inclusion of B7 genes in gag-env immunization results 332
in a transient (week 7) increase in the CTL response pre-challenge (this increase being 333
significant when both B7 genes are included in the inoculum) but a decreased CTL response 334
post-challenge. 335
336
3.1.2. T lymphocyte proliferative responses337
3.1.2.1. Effect of plasmid immunization  338
PBMC from the animals under study were stimulated with GAG protein (p14, p17 or p25) 339
and S.I. of proliferative responses determined (Fig. 2). Comparatively, the p14 and p25 proteins 340
frequently induced the lowest and the highest S.I., respectively. Within-group analysis revealed 341
that both groups immunized with B7 genes had a significantly increased (S.I. ≥ 3) early (week 7) 342
proliferative response against all of the Gag proteins. Also, between group comparisons (Fig. 2) 343
indicated that the early response (week 7) was significantly increased in the CD80/CD86 group 344
compared to the control group when using p17 as stimulatory protein; in both B7 groups 345
compared to the gag-env group using either p14 or p25. 346
347
3.1.2.2. Effect of MVA booster immunization348
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In both B7 immunized groups, boosting with recombinant MVA (week 10) resulted, by 349
week 12, in a further significant increase of the proliferative response compared to plasmid 350
immunization (weeks 0 and 7) responses using either p17 or p25 as stimulatory antigens. 351
Furthermore, within the gag-env group in the absence of B7 genes in the inoculum, the 352
proliferative response was significantly increased only after the MVA booster immunization 353
(using p17 and p25 protein for stimulation, significance not indicated on the graph). Analysis 354
between groups (Fig. 2) revealed that by week 12 animals receiving B7 genes had a 355
significantly increased response compared to the control group using p17 for stimulation. 356
Finally, the gag-env-CD80 group had a significantly higher response than the gag-env group 357
using either p14 or p17.358
359
3.1.2.3. Effect of VMV challenge360
By week 16, both groups receiving B7 maintained the proliferative responses observed 361
before challenge (week 12) and had significantly increased responses compared to the control 362
group using p14 or p17 (Fig. 2). However, the control group had a significantly increased 363
response when comparing in this group the post-challenge and the pre-challenge periods (using 364
p17 and p25 proteins, weeks 20 and 24, significance not indicated in the figure). Later post-365
challenge time points (weeks 20 and 24) showed similar responses in the different study groups. 366
Overall, immunization including B7 triggered an increased proliferative response to viral 367
antigen before and early after challenge compared to gag-env and control groups. After 368
challenge, the proliferative response was maintained at moderate levels in all groups until the 369
end of the experiment. 370
371
3.2. Specific antibody production372
373
Antibody titre determinations using a whole virus ELISA revealed that VMV antibodies 374
were not significantly produced before challenge in any of the groups (Fig. 3A). After challenge, 375
groups receiving CD80 (alone) or CD80 and CD86 had the highest antibody production 376
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compared to the control group, being significantly higher at weeks 16, 20 and 24 for the gag-377
env-CD80 group; and at weeks 16 and 20 for the gag-env-CD80-CD86 group. Compared with 378
the gag-env group, both B7 groups also had significantly higher antibody titres at week 16; and 379
the gag-env-CD80 group had increased titres at week 24. In all groups, the antibody titre 380
increased towards the end of the experimental period. These results were confirmed with a 381
commercial VMV antibody ELISA test (Elitest). More than 50 percent of the vaccinated 382
animals became seropositive (O.D. ratios >1) in this assay after challenge (by week 16) in each 383
of the immunized groups, whereas the control group reached this percentage later on (week 20). 384
WB determinations using whole virus antigen (not shown) provided information on 385
antibody specificity. Antibodies produced soon after challenge (by week 16) in both B7386
immunization groups had anti-ENV precursor (gp150) and anti-GAG (p25) specificities. 387
Furthermore, most of the B7 vaccinated animals produced anti-ENV gp44 transmembrane (TM) 388
protein antibodies, but only at late stages after challenge (week 24). Antibodies found by WB in 389
the gag-env group soon after challenge (weeks 16 and 20) were only against the ENV precursor, 390
anti-GAG antibodies appearing later on in this group (at week 24). The control group presented 391
antibodies only at week 24, having then anti-ENV and anti-GAG specificities. 392
Regarding NtAb production (Fig. 3B), the gag-env-CD80 and the gag-env vaccinated 393
animals showed significantly increased titres in the post-challenge (weeks 16, 20 and 24) 394
compared to the pre-challenge period (week 12). Interestingly, amongst the immunized groups, 395
NtAb titre was the lowest (at week 20) in the gag-env-CD80-CD86 group, as only 1 of the 8 396
animals within this group had NtAb at this time point. However, this difference was not 397
maintained, as 4 of the 8 animals became NtAb positive at week 24. Three of these 4 NtAb 398
positive animals, reached then high NtAb titres and were provirus positive. On the other hand, 399
among the 4 NtAb negative animals of this group, only one was provirus positive (see Section 400
3.3).401
Overall, no significant antibody response was detected in groups immunized with B7402
genes (CD80 alone or combined with CD86) and the other groups upon immunization and 403
booster. Although after challenge the B7 groups had a higher antibody response compared to the 404
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control group, significant NtAb production was detected the latest (week 24) in the gag-env-405
CD80-CD86 immunized animals and only in 50 percent of them.406
407
3.3. Proviral load after challenge408
409
Proviral load was measured in blood and other tissues by quantitative real time PCR 410
before (to verify the PCR-negative status) and after EV1 challenge (done at week 12) and the 411
proportion of provirus positive animals determined. All the animals were free of provirus before 412
challenge. 413
In blood, just after challenge (week 16), all groups showed at least one provirus positive 414
animal. During the post-challenge period, provirus was detected at least once in all the animals 415
vaccinated with gag-env or gag-env-CD80 and the majority of animals in the control group. 416
Significantly, only 50 percent of the animals were provirus positive in the gag-env-CD80-CD86417
group (Table 2), a proportion that was significantly lower than in the other immunized groups, 418
gag-env-CD80, gag-env and the control group. 419
Proviral load was also determined in other tissues (lung and MLN). Viral detection in one 420
of the four analysed pieces of the lung or in the MLN was considered indicative of infection. 421
Surprisingly, no provirus was detected in the MLN of the gag-env group, but when both target 422
tissues were analysed together, the gag-env-CD80-CD86 group showed again the lowest 423
infection level with only 25 percent of animals provirus positive (Table 2). 424
When analysing the three sampled tissues together (blood, lung and MLN), the group 425
including both B7 genes in the inoculum (gag-env-CD80-CD86) showed a significantly 426
decreased proportion of provirus positive animals compared with the other groups (50 vs. 100 427
percent).428
Proviral load was highly variable among the infected animals in all the groups (10-700 429
copies). There were no significant differences between groups in the proviral load amongst the 430
infected animals.431
432
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3.4. Post-mortem examination433
434
Lung and MLN were examined at necropsy. All the animals showed macroscopically 435
healthy lungs. Upon microscopic examination, most of them, including those of the gag-env and 436
control groups, showed bronchial associated lymphoid tissue hyperplasia in the absence of gross 437
clinical signs such as congestion and/or oedema. Follicular hyperplasia and interstitial 438
pneumonia in lungs and lymphoid follicle reactivity and cortical hyperplasia in MLN were 439
scored jointly, as described elsewhere [16], to determine the overall histological changes. The 440
results showed that groups immunized with B7 genes had a significantly higher score index than 441
the control group (Fig. 4). This augmented score was due to an increased frequency of animals 442
in these groups that presented: a) follicular hyperplasia in lung (all the B7 immunized animals 443
vs. 70 percent of the gag-env and 56 percent of control animals); b) a mild interstitial 444
pneumonia (62 percent vs. 50 and 0 percent of the animals in the B7 groups compared to gag-445
env and control groups, respectively); and c) follicular reactivity in MLN (all the B7 immunized 446
animals vs. 50 percent of the gag-env and 70 percent of control animals). Interestingly, 447
perivascular infiltrates were absent from lungs of both B7-immunized groups (except in 1 of the 448
16 animals) but generally present in the control and gag-env groups. 449
Altogether, these results demonstrate an increased lymphoid tissue reaction and the 450
absence of gross clinical signs in target organs (mild lung interstitial pneumonia and follicular 451
hyperplasia in lung and MLN), upon B7 adjuvant immunization-intratracheal challenge with 452
VMV. 453
454
4. Discussion455
456
Knowing that CD80 RNA levels in VMV infections are downregulated in clinically 457
affected animals [32], we investigated in this study whether the use of ovine B7 genes in 458
immunizations with VMV gag and env genes enhanced specific immune responses in sheep and 459
conferred significant protection after challenge in terms of viral infection and/or immune 460
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enhancement. For this, a combined vaccination strategy against VMV in sheep was applied, 461
consisting of PMED recombinant plasmid delivery [14, 15] followed by a subcutaneous boost 462
with recombinant MVA [15] and VMV challenge. This allowed the study of cellular and antibody 463
mediated immune responses along the experimental period and determination of proviral load as 464
well as investigation of histological changes at necropsy.465
Early CTL/Th1 responses after vaccination, previously studied in infections by HIV, SIV, 466
CAEV and EIAV, have been associated with protection in individuals challenged with the virus 467
[41-45]. Here, the earliest immune responses observed upon vaccination were mainly cellular, not 468
antibody mediated. An early CTL response was produced as a result of plasmid immunization (by 469
week 7) in both B7 immunization groups, being then significantly increased in the group 470
receiving both B7 genes. However, the response decreased after MVA boost (by week 12) and 471
further decreased in both B7 immunization groups, until disappearing in the group receiving both 472
CD80 and CD86 after challenge. In contrast, the proportion of precursor CTL-positive animals 473
had a tendency to increase in the control group in the post-challenge period. In a previous 474
vaccination-challenge study, using the same gag-env immunization approach without including 475
B7 genes in the inoculum, no CTL-positive animals were found by week 7, rather CTL responses 476
appeared later, after MVA boosting, and became significantly higher compared to unvaccinated 477
controls by week 20 ([15] and this study). However, by week 24 all the animals were provirus 478
positive by the end of the experimental period in that study. Also, with a gag-env mucosal 479
immunization approach, a very limited CTL response was obtained upon immunization and 480
challenge [16]. Altogether, these observations strongly suggest that inclusion of B7, and 481
particularly both B7 genes (CD80 and CD86) in the immunization inoculum leads to an early 482
(week 7) significant production of CTL precursors. Likely, these cells underwent clonal 483
expansion and re-distribution in the organism (week 12) and were maintained in a low proportion 484
in blood after virus clearance (weeks 16, 20 and 24). The enhancement of CTL responses when 485
incorporating CD86 into the vaccine is in agreement with a series of previous HIV studies in mice 486
[46-48] where inclusion of CD80 in the inoculum did not generate CTL responses. However, the 487
relative role of both CD80 and CD86 molecules remains controversial, as there are studies in 488
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mice which either propose the enhancement of both cellular and humoral responses when using 489
CD86 [49] or describe the enhancement of CTL responses when incorporating CD80 rather than 490
CD86 [50].491
Like CTL production, significantly increased proliferative responses against a GAG protein 492
were found as early as week 7 (upon plasmid immunization), but only in the group immunized 493
with both B7 genes, compared to unvaccinated controls. Upon MVA boosting (week 10), 494
proliferative responses became significantly increased in both groups receiving B7 genes. Using 495
the same immunization protocol in sheep immunized with gag-env (without including B7), the 496
proliferative response against a GAG protein was also found by weeks 7 and 12 [15]. Following 497
challenge (performed at week 12), proliferative responses against GAG proteins were 498
significantly increased compared to controls (week 16) in both studies and in work involving 499
sheep mucosal gag-env immunization [16]. Similarly to this work, a gag-pol plasmid 500
immunization study in chimpanzees demonstrated that inclusion of CD86 gene in the inoculum 501
augmented the viral-antigen specific lymphoproliferative responses [51]. Overall, this study 502
demonstrates that inclusion of B7 genes (especially if both genes are combined) in gag-env503
immunization results in increased early lymphocyte proliferative responses, and strongly suggests 504
that some of these lymphocytes may be involved in CTL activation. The group receiving both B7505
genes had a decreased proportion of provirus positive animals and a significantly increased early 506
CTL and proliferative responses after plasmid immunization, leading to a high clonal expansion 507
and strong memory cell production by the time of challenge. Similarly, in an in vitro study a role 508
for CD86 rather than CD80 in suppression of HIV replication has been linked to enhanced CD8+ 509
cell activity [52]. 510
Antibody (IgG), as detected by ELISA, was not produced upon plasmid or MVA 511
immunization in any of the immunization groups, which is in agreement with previous VMV 512
plasmid immunization studies in sheep [14, 16], and with work in mice on immunization with 513
HIV plasmids in the presence of CD80 or CD86 genes [49]. Just after challenge (week 16) and 514
until the end of the experimental period, groups receiving B7 genes produced both anti-ENV and 515
anti-GAG antibodies, as revealed by WB, whereas the gag-env group had anti-ENV but a very 516
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
low production of anti-GAG antibodies at weeks 16 and 20 and the control group did not show 517
either anti-ENV or anti-GAG antibodies until week 20. In natural infections, anti-ENV and GAG 518
p25 antibodies are usually produced the earliest [53] although there can be a delay in the 519
production of anti-ENV antibodies [54]. In this work, the delay was restricted to TM-ENV 520
antibodies, likely because some TM epitopes are less exposed. The presence of ENV- and 521
particularly GAG-specific antibodies in both of the B7 immunized groups early after challenge 522
could be due to increased costimulatory signals and pre-activation of the B cells as a result of 523
immunization (weeks 7 and 12) in these groups. 524
NtAb production was very limited in this study, increasing in all the groups towards the end 525
of the experimental period. The delay in NtAb production observed in the group receiving both 526
B7 genes (CD80 and CD86) may be related to a decreased viral exposure in this group after 527
challenge, with only 50 vs. 100 percent of provirus positive animals. Also the probability of 528
finding NtAb was decreased in provirus-free animals of this immunization group by week 24. A 529
similar association between the lack of NtAb production and decreased viral load/exposure has 530
been found in vaccinated animals of a previous VMV env-based immunization-challenge study 531
[14]. Furthermore, NtAb have been found in VMV vaccinated animals that become infected after 532
challenge [20]. NtAb were detected post-challenge in this study, and not in our previous 533
immunization study performed under the same experimental conditions but in the absence of B7 534
adjuvants [15]. This was most likely due to differences in the sensitivity of the neutralization 535
assay used in both studies, as here its readout was viral replication (using a -galactosidase 536
construct) whilst Niesalla et al. [15] detected syncytium formation. 537
An early, strong NtAb response has been linked to reduced CNS pathology after infection 538
of sheep with VMV [55], and neutralization escape mutants do arise in persistently infected 539
animals [56, 57]. However, there is mounting evidence that neutralization by antibody may not be 540
important in controlling SRLV infections [58, 59]. Likely, some of the NtAb detected in vitro are 541
inefficient in controlling the infection in vivo. On the other hand, in the immunodeficiency virus 542
field, antibodies functioning in antibody-dependent cellular cytotoxicity (ADCC) responses may 543
be important in controlling virus (SHIV) replication [58]. As VMV is primarily cell associated in 544
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vivo, ADCC may be a particularly important antibody effector function. However, IgG2 antibody 545
involved in ADCC, is not induced after VMV infection [36, 60] and induction of this isotype by 546
vaccination may provide a significant mode of protection. Future studies to determine which 547
antibody isotypes and which cellular and cytokine profiles are induced by prime-boost 548
vaccination regimens are needed.549
Significantly, PMED immunization using VMV gag and env genes, together with B7 genes 550
combined, triggered significantly increased early specific CTL and proliferative responses, 551
leading to the presence of precursor and effector memory T cells. These cells could be present in 552
the lung and the MLN, having local follicular hyperplasia (both) and a mild interstitial pneumonia 553
(lung) upon intratracheal challenge, as observed at necropsy. An increased reaction score in target 554
tissues (lesion) was also observed in a previous study on immunization with the combination of 555
the gag and env genes [15]. However, all the animals receiving B7 had overall mild 556
lesions/inflammatory signs. There was no disappearance of epithelial tissue and the lesions 557
(presence of lymphocytes, follicular hyperplasia, etc.) would be those expected from a transient 558
antigen exposure. None of the animals had clinical signs, macroscopic or strong microscopic 559
lesions, that might be considered irreversible. These tissue changes, observed at the third month 560
post-challenge (this work and previous studies;[15, 16]), might disappear when prolonging the 561
post-challenge period for about one year, as observed in previous work employing the same viral 562
dose and strain for challenge [14].563
The fate of lesions may be linked to the presence/absence of infection. In this regard, a 564
significant proportion (50%) of animals in the group receiving both B7 genes was provirus 565
negative while showing mild lesions, but in these animals, the immunization could have just 566
delayed the appearance of infection. If so, virus-associated clinical disease would be expected to 567
take more that one year to appear [14], taking into account the challenge dose used and the 568
prolonged period often required in lentiviral infections for target organs to present severe lesions. 569
Alternatively, these animals could have been really protected from the viral infection. In this case, 570
a progressive disappearance of the interstitial pneumonia and of follicular hyperplasia would be 571
expected as antigen exposure would be missing. In any case, the immune response was able to 572
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either eliminate the virus or delay the establishment of infection in these animals during the 573
experimental period. To distinguish between these alternatives, cell and cytokine profile 574
determinations in target tissues/organs would be relevant again in longer term pot-challenge 575
studies. These will also help to understand why the sensitization before challenge eventually 576
enhances or stops the lesion in these animals.577
In conclusion, in VMV gag-env vaccination, the use of B7 genes particularly in 578
combination (CD80 and CD86), induces early increased cellular responses (CTL and proliferative) 579
before challenge as well as antibody responses to viral antigens soon after challenge and enhances 580
protective effects against early infection while triggering an immune reaction of lymphoid tissue 581
in challenged-target organs. Overall, the use of B7 genes combined results in decreased infection, 582
but new strategies need to be explored in order to further increase the proportion of provirus-free 583
healthy animals in long term immunization-challenge approaches and determine the final 584
outcome and profile of the inflammatory reactions in target organs and related tissues. 585
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Legends769
770
Figure 1. CTL responses.771
The percentage of CTL positive animals in the control and immunization groups is shown. (*) 772
statistically significant differences between weeks of the experimental period in the percentage 773
of CTL positive animals according to Fisher's Exact test within each study group: in the gag-774
env-CD80-CD86 group, the percentage in week 7 was significantly higher (p = 0.025) than in 775
week 0; and in the gag-env group the percentage in week 20 was higher than in weeks 0, 7 (p = 776
0.004 in both cases) and 16 (p = 0.029).777
778
Figure 2. T cell proliferative responses.779
The antigen stimulation indices (S.I.) in the different groups throughout the study period (weeks 780
0 to 24) are shown, using as stimulatory antigen p14, p17 or p25 GAG proteins. Results are 781
expressed as box plots with the median of the group shown as a line and the interquartile range 782
represented by the box. (*) shows values significantly higher (p <0.05) than the control group 783
according to a Mann-Whitney test, found: for p14, gag-env-CD80 and gag-env-CD80-CD86784
groups at week 16; for p17, gag-env-CD80 group at weeks 12 and 16; and gag-env-CD80-CD86785
group at weeks 7, 12 and 16. (§) significantly higher (p<0.05) than gag-env group, found: for 786
p14, gag-env-CD80 group at weeks 7, 12 and 12; and gag-env-CD80-CD86 group at week 7; 787
for p17, gag-env-CD80 group at week 12; for p25, gag-env-CD80 and gag-env-CD80-CD86788
groups at week 7. See text for intra-group differences between time points.789
790
Figure 3. Antibody production against VMV. 791
Panel A shows antibody titres against VMV as detected by serial two-fold dilutions of sera from 792
sheep tested on a whole VMV ELISA at different time points. Serum were not considered 793
positive unless titre was >100. The results are represented by box plots indicating the median 794
value and the interquartile range. (*) titre greater than the control group (p <0.05, group gag-795
env-CD80 at weeks 16, 20 and 24; and group gag-env-CD80-CD86 at weeks 16 and 20); (§) 796
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titre greater than gag-env group (p <0.05, group gag-env-CD80 at weeks 16 and 24; group gag-797
env-CD80-CD86 at week 16), using Mann-Whitney tests.798
Panel B shows neutralization titres against VMV. Different dilutions of the sheep serum were 799
incubated with the virus. Neutralizing antibody titres were calculated as the reciprocal of the 800
serum dilution that caused neutralization in 50 % of viral infectivity in the inoculated cultures. 801
Median and interquartile range are represented in the box plot. (*) statistical differences 802
between pre-challenge and post-challenge periods within groups (p = 0.046 for gag-env; p = 803
0.043 for gag-env-CD80) by Wilcoxon tests. (§) statistical differences between gag-env-CD80-804
CD86 vs. gag-env and gag-env-CD80 groups (p = 0.05 and p = 0.038 respectively), using 805
Mann-Whitney tests.806
807
Figure 4. Post-mortem tissue examination.808
The mean pathology score ± standard error of the group in lung and mediastinal lymph 809
node is shown. (*) pathology score greater than the control group (p = 0.021 for gag-810
env-CD80; p = 0.009 for gag-env-CD80-CD86) using a Mann-Whitney test.811
812
813
Table 1
Inoculum received by the different study groups.
Inoculum
Animal group No. of 
animals
Plasmid prime and boosta
(Week 0, 4) 
MVA boostb
(Week 10)
Control 7 pN3 (30μg) MVA-pSC11
gag-env 7 pN3-gag (10μg) +pN3-env (10μg) 
+pN3 (10μg) 
MVA-gag+MVA-env
gag-env-CD80 8 pN3-gag (10μg) +pN3-env (10μg) 
+pN3-CD80 (10μg)
MVA-gag+MVA-env
gag-env-CD80-CD86 8 pN3-gag (10μg) +pN3-env (10μg) 
+pN3-CD80 (5μg) +pN3-CD86 (5μg)
MVA-gag+MVA-env
a Particle-mediated epidermal delivery, a total of 30 g DNA per animal.
b Subcutaneous; 2x108 pfu of modified vaccinia Ankara virus (MVA) (108 per recombinant vaccinia ) 
per animal.
Table(s)
Table 2
Percentage of animals with virus (PCR+) in blood and/or tissues after challenge with VMV. 
Group 
(No. of animals)
Blooda Other tissues Total (animals 
with virus in 
blood and/or other 
tissues)Lungb
Mediastinal 
lymph node Total
gag-env-CD80
(n=8)
100 37.5 50 71.4 100
gag-env-CD80-CD86
(n=8)
50c 25 12.5 25 50e
gag-env
(n=7)
100 42.8 0d 42.8 100
Control 
(n=7)
85.7 57.1 28.6 57.1 100
a Infection was considered to be present when at least one of the three time points analysed after 
challenge with VMV (weeks 16, 20 and 24) showed a positive reaction. 
b Infection was considered to be present when at least one of the four different lung pieces 
analysed showed a positive reaction. 
c In blood, statistical analysis showed that the group receiving both B7 genes (gag-env-CD80-
CD86) had fewer provirus positive animals than the group without costimulatory molecules 
(gag-env) (p = 0.05) as well as the group with CD80 alone (p = 0.038). 
d In tissues, statistical differences were found between the gag-env group and gag-env-CD80 in 
the mediastinal lymph node (p = 0.05).
e An animal was considered positive for infection when any positive reaction was found in blood 
and/or in the different tissues. The animals receiving gag-env-CD80-CD86 had a decreased 
percentage of infected animals when compared to the rest of the groups: gag-env-CD80 group 
(p = 0.038) and gag-env and control groups (p = 0.05) using Fisher Exact test.
Table(s)
Figure 1 de Andrés et al.
*
w0 w7 w12 w16 w20 w24
0
20
40
60
80
100
A. Control
w0 w7 w12 w16 w20 w24
0
20
40
60
80
100
B. gag-env
P
er
ce
n
ta
ge
 o
f 
C
T
L
 p
os
it
iv
e 
an
im
al
s 
*
w0 w7 w12 w16 w20 w24
0
20
40
60
80
100
C. gag-env -CD80
P
er
ce
n
ta
ge
 o
f 
C
T
L
 p
os
it
iv
e 
an
im
al
s 
Time (weeks)
w0 w7 w12 w16 w20 w24
0
20
40
60
80
100
D. gag-env -CD80-CD86
Figure(s)
Figure 2 de Andrés et al.
p17p14 p25
0
20
40
60
80
120
160
110
120
w0
w7
w12
0
20
40
60
80
80
§ §
0
20
40
60
* §§
St
im
ul
at
io
n 
in
de
x 
(S
.I
.)
§
§ *
*
0
20
40
60
80
w16
w20
w24
§
*
*
0
20
40
60
80
0
20
40
60
80
St
im
ul
at
io
n 
in
de
x 
(S
.I
.)
*
*
Group
Figure(s)
Figure 3 de Andrés et al
A
A
n
ti
b
od
y 
ti
tr
e
1000
2000
3000
4000
B
100
150
200
250
*
§
*
*
*
§
*
§
*
*
*
0
50
0
Group
Figure(s)
Figure 4 de Andrés et al.
0.10
0.15
0.20
P
at
h
ol
og
y 
sc
or
e 
in
d
ex
*
*
0
0.05
P
at
h
ol
og
y 
sc
or
e 
in
d
ex
Group
Figure(s)
